Patricia Villagrasa

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Francesco Schettini, Núria Chic, Fara Brasó‐Maristany et al. · npj Breast Cancer · 2021 · 655 citations · Full text

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Aleix Prat, Cristina Saura, Tomás Pascual et al. · The Lancet Oncology · 2019 · 191 citations

Breast Oncology, Medicine, Pharmacology +10

Repression of PTEN Phosphatase by Snail1 Transcriptional Factor during Gamma Radiation-Induced Apoptosis

Maria Escrivà, Sandra Peiró, Nicolás Herranz et al. · Molecular and Cellular Biology · 2008 · 188 citations · Full text

Pten Promoter, Pten Promoter Increases, Molecular Regulation +17

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

Sara M. Tolaney, Paolo Tarantino, Noah Graham et al. · The Lancet Oncology · 2023 · 151 citations

Breast Oncology, Oncology, Breast Cancer +6

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso‐Sousa et al. · Breast Cancer Research · 2020 · 141 citations · Full text